ASH News Daily 2012 - Saturday, December 8, 2012 - (Page B-4)

disease, local trauma, including poorly fitting dentures). Many reports of ONJ involved patients wi including osteomyelitis. Cancer patients should maintain good oral hygiene and should have a preventive dentistry prior to treatment with bisphosphonates. While on treatment, these patient dental procedures, if possible, as recovery may be prolonged. For patients who develop ONJ bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring de procedures, there are no data available to suggest whether discontinuation of bisphosphona Thank you to the following companiesthe risk of ONJ. A causal relationship between bisphosphonate use and ON treatment reduces that provide educational support for the 2012 ASH Annual Meeting: (These acknowledgments reflectClinical judgment of the treating physician should guide the managemen has not been established. contributions made prior to November 16, 2012.) plan of each patient based on individual benefit/risk assessment. ZOMETA should not be used during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant. If the patient becomes pregnant or plans to breast-feed while taking this drug, the patient should be apprised of the potential harm to the fetus or baby. In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pai has been reported in patients taking bisphosphonates including ZOMETA. Discontinue use if seve symptoms develop, and a subset of patients had recurrence of symptoms Program) Hematology 2012 (the Education when rechallenged w Hematology 2012the same drug or Program) (the Education another bisphosphonate. There have been reports of bronchoconstriction in a ASH Abstracts Online ASH Abstracts on Flash Drive sensitive patients receiving bisphosphonates. Insufficient data exist on how to safely use ZOMETA in HCM patients with hepatic impairment. Acute-phase reaction symptoms can occur in HCM patients, with fever most commonly report with ZOMETA vs. 33% with pamidronate). Patients may occasionally experience flu-like syndro chills, flushing, bone pain and/or arthralgias and myalgias). The most common adverse events (≥10% clinical trials, regardless of causality, with ZOMETA 4 mg (n=86) were as follows: fever (44%), nau Hematology 2012 (the Education Program) constipation (27%), anemia (22%), dyspnea (22%), diarrhea (17%), abdominal pain (16%), pro cancer (16%), insomnia (15%), vomiting (14%), anxiety (14%), urinary tract infection (14%), hypop (13%), confusion (13%), agitation (13%), moniliasis (12%), hypokalemia (12%), coughing (1 pain (12%), hypotension (11%), and hypomagnesemia (11%). In controlled HCM clinical trials, a orporAte riendS (5-10% frequency) occurring in greater incidence with ZOMETA than pamidronate include: asthen ASHleg edema, the support it receives throughout the year from the thrombocytopenia, pancytopenia, non-spe is grateful for mucositis, dysphagia, granulocytopenia, following companies: hypocalcemia, dehydration, arthralgias, headache and somnolence. Injection site reactions (redness been infrequently reported. The most common adverse events (≥15%) in bone metastases clinical trials, regardless of causalit 4 mg (n=1031) were as follows: bone pain (55%), nausea (46%), fatigue (39%), anemia (33% vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15% (15%). Patients should also be made aware of the potential for abdominal pain. Ocular adverse events may occur with bisphosphonates, including ZOMETA. Cases of uveitis, s conjunctivitis, iritis, and orbital inflammation including orbital edema have been reported during po some cases, symptoms resolved with topical steroids. Caution is advised when bisphosphonates, including ZOMETA, are administered with aminoglyco and potentially nephrotoxic drugs. Patients with multiple myeloma and bone metastases due to solid tumors should be administ supplement of 500 mg and a multiple vitamin containing 400 IU of vitamin D daily. 2012 ASH Annual Meeting ASH C F Farbe/colour: PANTONE 288 CV References: 1. Rosen LS, Gordon D, Kaminski M, et al; Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group. Long-term effica compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast ca blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 2. Wu EQ, Bensimon AG, Marynchenko M, et al. Comparison of skele patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011;11:326-335. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33. Please see full Prescribing Information. Please see brief summary of full Prescribing Information on the following pages. © 2011 Novartis September 2011 F:10.75” 

Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012

ASH News Daily 2012 - Saturday, December 8, 2012

https://www.nxtbookmedia.com